Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia
研究单位：[1]Daiichi Sankyo Co., Ltd.[2]Sichuan Cancer Hospital,Chengdu,China,610041[3]Sun Yat-sen University Cancer Center,Guangdong,China,510060[4]The First Affiliated Hospital of Anhui Medical University,Hefei,China,230022[5]Hubei Cancer Hospital,Hubei,China,430079[6]Shanghai Changhai Hospital,Shanghai,China,200433[7]Tianjin Medical University Hospital,Tianjin,China,300060[8]Second Affiliated Hospital ZheJiang University School of Medicine,Zhejiang,China,310017[9]Henan Cancer Hospital,Zhengzhou,China,450003[10]Queen Mary Hospital,Pok Fu Lam,Hong Kong[11]Prince of Wales Hospital,Sha Tin,Hong Kong[12]Tuen Mun Hospital,Tuen Mun,Hong Kong[13]Dong-A University Hospital,Busan,Korea, Republic of[14]Chungbuk National University Hospital,Cheongju-si,Korea, Republic of,28644[15]Kyungpook National University Chillgok Hospital,Deagu,Korea, Republic of[16]Pusan National University Yangsan Hospital,Gyeongsangnam-do,Korea, Republic of[17]Kangbuk Samsung Hospital,Seoul,Korea, Republic of,04514[18]Samsung Medical Center,Seoul,Korea, Republic of,06351[19]Chung-Ang University Hospital,Seoul,Korea, Republic of,06973[20]Korea University Anam Hospital,Seoul,Korea, Republic of[21]Seoul National University Hospital,Seoul,Korea, Republic of[22]Severance Hospital,Seoul,Korea, Republic of[23]Chiayi Chang Gung Memorial Hospital,Chiayi City,Taiwan,61363[24]Kaohsiung Chang Gung Memorial Hospital,Kaohsiung,Taiwan[25]Kaohsiung Medical University Hospital,Kaohsiung,Taiwan[26]China Medical University Hospital,Taichung,Taiwan[27]National Cheng Kung University Hospital,Tainan,Taiwan,704[28]Chi Mei Medical Center,Tainan,Taiwan[29]Taipei Veterans General Hospital,Taipei,Taiwan,112[30]Koo Foundation Sun Yat-Sen Cancer Center,Taipei,Taiwan[31]MacKay Memorial Hospital,Taipei,Taiwan[32]Linkou Chang Gung Memorial Hospital,Taoyuan,Taiwan,33305
This study will be conducted to understand real-world treatment patterns, participant characteristics (demographic and clinico-pathological characteristics), clinical outcomes and safety of different treatment regimens, and healthcare resource utilization in East Asia for HER2-positive locally advanced or metastatic gastric or gastroesophageal adenocarcinoma (de novo advanced disease, relapsed/progressed) in a real-world setting.
